Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction

Citation
P. Iglesias et al., Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction, THYROID, 11(11), 2001, pp. 1043-1048
Citations number
28
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
THYROID
ISSN journal
10507256 → ACNP
Volume
11
Issue
11
Year of publication
2001
Pages
1043 - 1048
Database
ISI
SICI code
1050-7256(200111)11:11<1043:SIGFT1>2.0.ZU;2-P
Abstract
Thyroid hormones play a role in the regulation of insulin-like growth facto r type 1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) expression, and both IGF-1 and IGFBPs have been shown to be related to the function and growth of the thyroid. Our aim was to evaluate serum concentr ations of IGF-1, IGFBP-1, and IGFBP-3 in patients with thyroid dysfunction before and after normalization of thyroid function. The study was performed in 86 patients with thyroid dysfunction (43 hyperthyroid and 43 hypothyroi d. patients) and 17 euthyroid subjects. Serum growth hormone (GH), insulin, IGF-1, IGFBP-1, and IGFBP-3 were measured in all patients before and after normalizing serum thyroid hormone concentrations. Hyperthyroid patients sh owed IGF-1 (198.8 +/- 17.0 mug/L) and IGFBP-3 levels (4.2 +/- 0.2 mg/L) sim ilar to those found in the control group (217.9 +/- 20.3 mug/L and 4.2 +/- 0.3 mg/L, respectively). After therapy these levels significantly decreased to 156.6 +/- 11.1 mug/L (p < 0.01) and 3.3 +/- 0.1 mg/L (p < 0.001), respe ctively. IGFBP-1 concentrations were clearly higher than those found in con trols (22.7 +/- 2.6 vs. 5.7 +/- 1.5 mug/L, p < 0.001) and exhibited a signi ficant reduction after therapy for thyroid hyperfunction (11.0 +/- 1.7 mug/ L, p < 0.001). Patients with hypothyroidism showed serum concentrations of IGF-1 (161.5 +/- 13.1 mug/L, p < 0.05) and IGFBP-3 (3.2 +/- 0.3 mug/L, p < 0.05) significantly lower than those found in healthy volunteers. However, replacement therapy with levothyroxine did not induce any significant modif ication of these concentrations (152.6 +/- 10.6 mug/L and 3.2 +/- 0.2 mg/L, respectively). Similarly, patients with thyroid hypofunction exhibited rai sed levels of IGFBP-1 (15.5 +/- 0.9 mug/L, p < 0.05 vs. control group) that were significantly decreased after therapy (8.8 <plus/minus> 1.4 mug/L, p < 0.01). The results of the present study show that thyroid status affects GH/IGF axis. Hypothyroidism is associated with significant reductions of IG F-1 and IGFBP-3, and IGFBP-1 is elevated in both hypothyroidism and hyperth yroidism.